Astonea Labs

Who are the top shareholders of the Astonea Labs?

Astonea Labs is primarily owned by its promoters, who hold the majority of shares with no pledged holdings. There are no mutual funds, foreign institutional investors, or notable individual public shareholders involved.

Astonea Labs is primarily owned by its promoters, who hold the majority of the shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no notable individual investors or public shareholders listed. This indicates a concentrated ownership structure primarily focused within the promoter group.

Has Astonea Labs declared dividend?

No Dividend History Available

How has been the historical performance of Astonea Labs?

Astonea Labs has shown gradual profitability improvement over the past three years, with a profit before tax rising from 0.00 Cr in March 2022 to 5.00 Cr in March 2024. Cash flow from operating activities turned positive at 4.00 Cr in March 2024, while cash flow from investing activities remained negative.

Answer:<BR>The historical performance of Astonea Labs shows a gradual improvement in profitability over the past three years, despite the absence of standalone annual results and balance sheet data.<BR><BR>Breakdown:<BR>In the cash flow results, Astonea Labs reported a profit before tax of 5.00 Cr in March 2024, a significant increase from 1.00 Cr in March 2023 and up from 0.00 Cr in March 2022. Adjustments remained stable at 6.00 Cr for both March 2024 and March 2023, while it was slightly lower at 5.00 Cr in March 2022. Changes in working capital showed a decrease in negative values, with -7.00 Cr in both March 2024 and March 2023, compared to -10.00 Cr in March 2022. Consequently, cash flow after changes in working capital improved to 4.00 Cr in March 2024, up from 0.00 Cr in March 2023 and a negative 4.00 Cr in March 2022. Cash flow from operating activities also turned positive at 4.00 Cr in March 2024, contrasting with -1.00 Cr in March 2023 and -4.00 Cr in March 2022. However, cash flow from investing activities was negative, amounting to -7.00 Cr in March 2024, compared to -3.00 Cr in the previous two years. Cash flow from financing activities decreased to 3.00 Cr in March 2024 from 4.00 Cr in March 2023 and 8.00 Cr in March 2022. Overall, the net cash inflow/outflow remained at 0.00 Cr for all three years, indicating no change in cash position.

Who are the peers of the Astonea Labs?

Astonea Labs' peers include Coral Labs, Bafna Pharma, Syschem (India), Aarey Drugs, Panch.Organics, Krebs Biochem, Auro Labs, Bal Pharma, BDH Industries, and Tyche Industries. In terms of management risk, growth, and capital structure, Auro Labs and Coral Labs stand out positively, while Astonea Labs shows average performance in these areas.

Peers: The peers of Astonea Labs are Coral Labs., Bafna Pharma., Syschem (India), Aarey Drugs, Panch.Organics, Krebs Biochem, Auro Labs., Bal Pharma, BDH Industries, and Tyche Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Auro Labs. and BDH Industries, while Average management risk is found at Aarey Drugs, Bal Pharma, and Astonea Labs, and the rest. Below Average management risk is noted at Coral Labs., Bafna Pharma., and Syschem (India). In terms of Growth, Good growth is seen at Coral Labs., Bafna Pharma., Astonea Labs, and Bal Pharma, while Average growth is noted at Syschem (India) and Below Average growth is found at Aarey Drugs, Panch.Organics, and the rest. For Capital Structure, Excellent capital structure is observed at Coral Labs. and Panch.Organics, Good capital structure is noted at Bafna Pharma. and Auro Labs., while Below Average capital structure is found at Astonea Labs, Bal Pharma, and the rest.<BR><BR>Return Snapshot: Auro Labs. has the highest 1-year return at 68.93%, while Panch.Organics has the lowest at -45.84%. Astonea Labs.' 1-year return is not available for comparison. Additionally, the six-month returns for Coral Labs., Panch.Organics, Bal Pharma, and BDH Industries are negative.

What does Astonea Labs do?

Astonea Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 188 Cr. It has no recent sales or profit reports, a P/E ratio of 34.00, and a high debt-equity ratio of 3.51.

Overview: <BR>Astonea Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. There are no sales and profit reports available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 188 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 3.51 <BR>Return on Equity: 44.70% <BR>Price-to-Book: 15.55<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Astonea Labs?

As of 24th July, Astonea Labs Ltd has a market capitalization of 187.00 Cr, classifying it as a Micro Cap company. Recent quarterly performance data, including Net Sales and Net Profit, is unavailable, while the balance sheet for March 2024 shows Shareholder's Funds of 11.97 Cr and Total Assets of 80.89 Cr.

As of 24th July, Astonea Labs Ltd has a market capitalization of 187.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is not available, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 11.97 Cr and Total Assets valued at 80.89 Cr.

Is Astonea Labs overvalued or undervalued?

As of August 28, 2025, Astonea Labs is considered very expensive with a PE ratio of 34.32, significantly higher than its peers, indicating overvaluation and underperformance, as it has declined 3.48% recently compared to a 2.34% drop in the Sensex.

As of 28 August 2025, Astonea Labs' valuation grade has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 34.32, a Price to Book Value of 15.34, and an EV to EBITDA of 14.93. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Astonea Labs' PE ratio is higher than Sun Pharma's 33.18 and significantly above Cipla's attractive PE of 23.65. The PEG ratio of Astonea Labs stands at 0.00, which is unusual and raises concerns about future growth expectations. Recent stock performance shows a decline of 3.48% over the past week, while the Sensex fell only 2.34%, reinforcing the notion that Astonea Labs is not only overvalued but also underperforming relative to the broader market.

When is the next results date for Astonea Labs?

Astonea Labs will announce its results on 10 November 2025.

Astonea Labs is scheduled to declare its results on 10 November 2025.

Which are the latest news on Astonea Labs?

Why is Astonea Labs Ltd falling/rising?

As of 01-Feb, Astonea Labs Ltd's stock price is stable at 156.00, but it has declined by 2.50% over the past week and 4.59% year-to-date. Despite erratic trading and underperformance compared to its sector, there is increased investor interest indicated by a 150% rise in delivery volume on January 29.

As of 01-Feb, Astonea Labs Ltd's stock price is currently stable at 156.00, with no change recorded (0.00%). However, the stock has shown a decline of 2.50% over the past week, while it has remained unchanged over the past month. Year-to-date, the stock has decreased by 4.59%, which is slightly better than the Sensex's decline of 5.28% during the same period.<BR><BR>Today's performance indicates that Astonea Labs Ltd has underperformed its sector by 2.6%. Additionally, the stock has experienced erratic trading, having not traded on 2 out of the last 20 days. In terms of moving averages, the stock is currently higher than its 50-day moving average but lower than its 5-day, 20-day, 100-day, and 200-day moving averages, suggesting mixed signals regarding its short-term performance.<BR><BR>On a more positive note, there has been a notable increase in investor participation, with delivery volume on January 29 rising by 150% compared to the 5-day average. This indicates a growing interest among investors, despite the stock's overall underperformance in the short term. The liquidity of the stock is also sufficient for trading, as it is based on 2% of the 5-day average traded value.<BR><BR>In summary, while Astonea Labs Ltd's stock price is stable at the moment, the recent trends indicate a decline in performance over various periods, coupled with erratic trading patterns, which contribute to the perception of the stock's falling status.